HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

NCT06386263 · clinicaltrials.gov ↗

COMPLETED

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Breast Cancer
Metastatic Breast Cancer
HER2-low Expressing Breast Cancer
HER2-positive Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan

Sponsor

AstraZeneca

Collaborators

[object Object]